Talis Biomedical Corporat... (TLIS)
undefined
undefined%
At close: undefined
0.00
-100.00%
After-hours Dec 31, 1969, 07:00 PM EST

Company Description

Talis Biomedical Corporation operates as a molecular diagnostic company.

The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases.

It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.

In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus.

Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Talis Biomedical Corporation
Talis Biomedical Corporation logo
Country United States
IPO Date Feb 12, 2021
Industry Medical - Devices
Sector Healthcare
Employees 99
CEO Robert Kelley MBA

Contact Details

Address:
230 Constitution Drive
Menlo Park, California
United States
Website https://talisbio.com

Stock Details

Ticker Symbol TLIS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001584751
CUSIP Number 87424L108
ISIN Number US87424L2079
Employer ID 00-0000000
SIC Code 3826

Key Executives

Name Position
Robert Kelley MBA Chief Executive Officer & Director
Rebecca Markovich Interim Chief Financial Officer
Gillian Green Company Secretary
Jill Green Senior Vice President of Legal
Liang Li Ph.D. Co-Founder and Director of Technology & Strategy
Margaret Barrett M.S. Controller

Latest SEC Filings

Date Type Title
Oct 10, 2024 SC 13D/A [Amend] Filing
Sep 30, 2024 15-12G Filing
Sep 20, 2024 25-NSE Filing
Sep 17, 2024 8-K Current Report
Sep 09, 2024 S-8 POS Filing
Sep 09, 2024 S-8 POS Filing
Sep 09, 2024 S-8 POS Filing
Sep 09, 2024 S-8 POS Filing
Sep 09, 2024 4 Filing
Sep 06, 2024 8-K Current Report